tradingkey.logo
tradingkey.logo

enVVeno Medical Corp

NVNO
View Detailed Chart
10.745USD
+0.235+2.24%
Market hours ETQuotes delayed by 15 min
4.84MMarket Cap
LossP/E TTM

enVVeno Medical Corp

10.745
+0.235+2.24%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.24%

5 Days

-7.05%

1 Month

+7.45%

6 Months

+1045.40%

Year to Date

-4.30%

1 Year

+290.73%

View Detailed Chart

TradingKey Stock Score of enVVeno Medical Corp

Currency: USD Updated: 2026-03-27

Key Insights

enVVeno Medical Corp's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 186 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

enVVeno Medical Corp's Score

Industry at a Glance

Industry Ranking
186 / 391
Overall Ranking
332 / 4542
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

enVVeno Medical Corp Highlights

StrengthsRisks
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Overvalued
The company’s latest PE is -0.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 175.24K shares, decreasing 26.68% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.47K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.32.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

enVVeno Medical Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

enVVeno Medical Corp Info

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Ticker SymbolNVNO
CompanyenVVeno Medical Corp
CEOBerman (Robert A)
Websitehttps://envveno.com/
KeyAI